Penumbra Inc.
Penumbra Reports Strong 2023 Financial Results and 2024 Projections
Summary
Penumbra, Inc. reported robust financial results for the fourth quarter and full year 2023, with total revenue of $284.7 million and $1.06 billion, respectively, representing increases of 28.7% and 25.0% year-over-year. The company also provided financial projections for 2024, anticipating total revenue growth of 16% to 20%. Key highlights include a 42.4% increase in thrombectomy product sales for the fourth quarter and a 32.5% increase for the full year. Non-GAAP income from operations and adjusted EBITDA also saw significant growth, with $37.4 million and $53.4 million for the fourth quarter, and $101.3 million and $170.6 million for the full year, respectively.
Profitelligence Alerts
Get alerts for PEN
Be first to know when Penumbra Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Penumbra Inc.
Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.
Official SEC Documents
Advertisement